Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Scambia

Showing results (541-550 of 551) with videos related to

Pageof 56
Sort By:
NPJ Precision Oncology|January 19, 2026
Deciphering brain metastasis in epithelial ovarian cancer: multimodal analysis and potential biomarkersR Trozzi, M Salvi, M Karimi, et al.
ESMO Open|April 2, 2025
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studyC Marchetti, A Fagotti, R Fruscio, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|March 26, 2019
Imaging in gynecological disease (15): clinical and ultrasound characteristics of uterine sarcomaM Ludovisi, F Moro, T Pasciuto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancerM C Piccirillo, G Scambia, A Bologna, et al.
European Journal of Cancer (Oxford, England : 1990)|December 8, 2020
Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort studyD Cibula, L Dostalek, P Hillemanns, et al.
ESMO Open|May 20, 2025
HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparibL Beltrame, L Mannarino, A Sergi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2024
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapyS Pignata, D Califano, D Lorusso, et al.
ESMO Open|September 26, 2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trialE D Capoluongo, B Pellegrino, L Arenare, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|September 30, 2022
Benign descriptors and ADNEX in two-step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohortC Landolfo, T Bourne, W Froyman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2025
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancerP Harter, F Trillsch, A Okamoto, et al.
Pageof 56

Showing results (541-550 of 551) with videos related to

Sort By:
Pageof 56
NPJ Precision Oncology|January 19, 2026
Deciphering brain metastasis in epithelial ovarian cancer: multimodal analysis and potential biomarkersR Trozzi, M Salvi, M Karimi, et al.
ESMO Open|April 2, 2025
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studyC Marchetti, A Fagotti, R Fruscio, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|March 26, 2019
Imaging in gynecological disease (15): clinical and ultrasound characteristics of uterine sarcomaM Ludovisi, F Moro, T Pasciuto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancerM C Piccirillo, G Scambia, A Bologna, et al.
European Journal of Cancer (Oxford, England : 1990)|December 8, 2020
Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort studyD Cibula, L Dostalek, P Hillemanns, et al.
ESMO Open|May 20, 2025
HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparibL Beltrame, L Mannarino, A Sergi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2024
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapyS Pignata, D Califano, D Lorusso, et al.
ESMO Open|September 26, 2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trialE D Capoluongo, B Pellegrino, L Arenare, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|September 30, 2022
Benign descriptors and ADNEX in two-step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohortC Landolfo, T Bourne, W Froyman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2025
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancerP Harter, F Trillsch, A Okamoto, et al.
Pageof 56